Excited to share our research with the @NIH AMP AIM on plasmacytoid dendritic cells at #PhillyDerm society meeting! Congrats to Sarah June for taking first place!
New #ClinicalTrial update:
@Biogen announced positive results from the Phase 2 part of the AMETHYST Phase 2/3 study, showing that the litifilimab significantly reduced skin disease activity in cutaneous lupus erythematosus (CLE).
Learn more: bit.ly/4bWFTN4#LupusResearch#Lupus
Presented at #AAD2026:
In the VALOR trial of brepocitinib in adults with dermatomyositis, the 30-mg dose (but not the 15-mg dose) led to greater improvement on a composite myositis index at 52 weeks than placebo. Serious infections were more frequent with the 30-mg dose. Full trial results: nejm.org/doi/full/10.1056/NE…@AADmember
ALT A figure showing the Total Improvement Score among the patients with treatment-resistant dermatomyositis who received 30 mg of brepocitinib, 15 mg of brepocitinib, or placebo daily for 52 weeks.
Noted dermatologist Victoria Werth speaks to @TheLupusForum about the importance of the U.S. FDA accepting CLASI as a tool to measure the effectiveness of potential treatments for cutaneous lupus – a debilitating type of lupus that targets the skin for which there are no specific treatments.
Dr. Werth credits this acceptance to the work of the public-private partnership — the Lupus Accelerating Breakthroughs Consortium — convened by the LRA with the FDA to advance development of new treatments for lupus.
Check it out below ⬇️
lupusresearch.org/in-the-new…#lupus#lupusresearch
What are the key insights in cutaneous lupus from SLEuro 2026?
Victoria Werth shares the key takeaways from her session on cutaneous lupus and highlights important clinical and research perspectives discussed at the meeting.
🎥 Watch the full video here: lupus-forum.com/congress/13/…#Lupus#SLEuro2026#SLEuro#MedicalEducation
The effect of belimumab on mucocutaneous and vasculitis manifestations in patients with systemic #lupus erythematosus: A large pooled post hoc analysis @SageJournalsjournals.sagepub.com/doi/10.…
Now published: The 2025 ACR Guideline for the Treatment of Systemic Lupus Erythematosus
📄 Read the paper: acr.tw/47mkegj
ℹ️ See additional content and resources on this guideline at acr.tw/4mbHK4W
ALT LEGEND:
Overview of the recommended management for systemic lupus erythematosus (SLE). This schematic illustrates the approach to SLE treatment, with organ-specific therapies presented in separate boxes and stratified by disease severity.
The order of the medications in each box does not indicate preference unless noted otherwise.
Lupus nephritis treatment is addressed in the 2025 American College of Rheumatology Guideline for the Screening, Treatment, and Management of Lupus Nephritis.
(see paper for footnotes)
CONGRESS | #ACR25 | PRESENTATION
Victoria Werth, University of Pennsylvania, discusses applying the 2025 ACR guidelines to the treatment and management of cutaneous lupus; highlighting the considerations for clinical practice using two patient case examples. Key recommendations were outlined for cutaneous lupus erythematosus (CLE), bullous LE, chilblain lupus and vasculitis.
Follow our live feed for more updates: loom.ly/2QI_IUA
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.
#lupus#MedEd#MedicalCongress#RheumTwitter@werthlab@Penn
Another busy rheum-derm clinic in the books with many residents, researchers, and students! We’re looking forward to seeing everyone at @RheumDermSoc meeting and #ACR2025@ACRheum
This w'end #MIHRA leadership in Dallas #MyoCon. @werthlab rec'd Science Award‼️ Intro'd by past recipient& MIHRA board member @HeleneAlex1969 MIHRA Mayo board members FloranneErnste & @ElieNaddaf3 rec'd Care Award‼️ Creating a World Where We Cure Myositis Together ✨️❤️ 🧡💛✨️